// App-Quantinova.ai

FRI0493 (2018) : Pet/ct in patients with giant cell arteritis after 1 year of treatment with tocilizumab plus prednisone taper or only prednisone taper

Researchers

Presenter

  • A. Ishai

Principal Investigators

  • C. Maldini

  • J.H. Stone

  • G.F. Espigol-Frigole

  • M.C. Cid

  • D. Blockmans

  • D. Carmellino

  • M. Cimmino

  • F. Muratore

  • R. Slart

  • C. Salvarani

  • F. Narvaez Garcia

  • S. De Vita

  • B. Hellmich

  • S. Dimonaco

  • M. Klearman

  • A. Petho-Schramm

  • K. Tuckwell

  • N. Collinson

  • A. Tawakol

  • S. Unizony

Medical Centers

  • MGH, Boston, MA

  • UMC Groningen, Groningen, Netherlands

  • Hospital Privado, Cordoba, Argentina

  • IDIBAPS, Badalona, Spain

  • Gasthuisberg Hospital, Leuven, Belgium

  • Genoa University, Genoa

  • UNIMORE, Reggio Emilia, Italy

  • GEICO and Bellvitge Hospital, Barcelona, Spain

  • Udine University, Udine, Italy

  • Medius Klinik Kirchheim, Kirchheim-Teck, Germany

  • Roche Products Limited, Welwyn Garden City

  • Genentech, San Francisco, CA

  • Roche Products, Basel, Switzerland

Locations

  • United States

  • Netherlands

  • Argentina

  • Spain

  • Belgium

  • Italy

  • Germany

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

Disease

  • Giant cell arteritis

Biomarkers

  • 18F-fluorodeoxyglucose

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Tocilizumab

  • Prednisone

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved